Synthetic Audiences in Healthcare Media: Questions Before Use
A claim-and-validation checklist for synthetic and modeled audiences in healthcare media that separates privacy benefits from predictive validity.
The short answer
Synthetic audiences are a growing category in healthcare marketing. The term covers several different things: audiences built from synthetic data that mimics real populations, AI-modeled lookalike audiences, and simulated personas used for planning. Vendors often promise privacy benefits and strong performance. Those are separate claims, and each needs evidence.
What "synthetic" might mean
| Type | Description | Main claim |
|---|---|---|
| Synthetic data | Artificial records generated to reflect patterns in real data | Privacy protection while preserving patterns |
| Modeled audiences | Real people selected by a model trained on seed data | Scale beyond the seed while keeping relevance |
| Simulated personas | AI-generated profiles for planning or testing | Faster research and planning |
Ask vendors which they mean. The questions differ.
Separate privacy claims from performance claims
A synthetic data approach may reduce privacy risk. That does not mean audiences built from it will perform well. Conversely, a modeled audience may perform well but still involve personal data. Evaluate each claim separately.
Questions about privacy
- What real data was used to create or train the synthetic data or model?
- Can individuals be re-identified from the synthetic data?
- How was privacy risk tested?
- Does the approach fall under health data laws that apply to the source data?
The NIST Privacy Framework offers a structure for these questions.
Questions about validity
- How well does the synthetic or modeled audience predict real behavior?
- What was it validated against, and when?
- Does it perform equally well across subgroups? See bias audits.
- How does it compare with non-synthetic alternatives in a head-to-head test?
Red flags
- Claims that synthetic data is "fully anonymous" without describing testing.
- Performance claims based only on case studies from other brands.
- Unwillingness to explain the source data.
- No validation against real outcomes.
Test before scaling
Run a controlled test comparing the synthetic or modeled audience with your current approach, using the same measurement partner and period. See audience data evaluation and provenance questions.
Simulated personas for planning
AI-generated personas can speed up brainstorming. They are not research. They reflect patterns in training data, which may not represent your patients. Validate important assumptions with real research before building a plan on them.
Practical takeaway
For any synthetic audience product, write two separate evaluations: one for privacy and one for validity. Require evidence for both before buying, and test against your current approach before scaling.
Sources
- NIST Privacy Framework
- NIST AI Risk Management Framework
- FTC, Health Breach Notification Rule: The Basics for Business
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.